Leading Global Investor in Energy, Innovation and Efficiency LP CONNECTION



TargeGen is a vascular biology focused biopharmaceutical company that primarily develops treatments associated with a broad range of human diseases including heart attack, cancer, and eye diseases (macular degeneration, diabetic macular edema, diabetic retinopathy), as well as many other serious medical conditions. TargeGen was acquired by Sanofi-aventis.

9380 Judicial Drive, San Diego, CA 92121
Tel: 858-678-0760 www.sanofi.us
  • TargeGen was acquired by Sanofi-aventis.